Serum, plasma and erythrocyte membrane lipidomes in infants fed formula supplemented with bovine milk fat globule membranes by Grip, Tove et al.
CLINICAL RESEARCH ARTICLE
Serum, plasma and erythrocyte membrane lipidomes in infants
fed formula supplemented with bovine milk fat globule
membranes
Tove Grip1, Thomas S. Dyrlund2, Linda Ahonen2, Magnus Domellöf1, Olle Hernell1, Tuulia Hyötyläinen3, Mikael Knip4,5,6, Bo Lönnerdal7,
Matej Orešič8,9 and Niklas Timby1
BACKGROUND: Supplementation of formula with bovine milk fat globule membranes has been shown to narrow the gap in
immunological and cognitive development between breast-fed and formula-fed infants.
METHOD: In a double-blinded randomized controlled trial 160 formula-fed infants received an experimental formula (EF),
supplemented with bovine milk fat globule membranes, or standard formula until 6 months of age. A breast-fed reference group
was recruited. Lipidomic analyses were performed on plasma and erythrocyte membranes at 6 months and on serum at 4 and
12 months of age.
RESULTS: At 6 months of age, we observed a significant separation in the plasma lipidome between the two formula groups,
mostly due to differences in concentrations of sphingomyelins (SM), phosphatidylcholines (PC), and ceramides, and in the
erythrocyte membrane lipidome, mostly due to SMs, PEs and PCs. Already at 4 months, a separation in the serum lipidome was
evident where SMs and PCs contributed. The separation was not detected at 12 months.
CONCLUSIONS: The effect of MFGM supplementation on the lipidome is likely part of the mechanisms behind the positive
cognitive and immunological effects of feeding the EF previously reported in the same study population.
Pediatric Research (2018) 84:726–732; https://doi.org/10.1038/s41390-018-0130-9
INTRODUCTION
Human milk is the optimal nutrition during early infancy, and
WHO, UNICEF, and the ESPGHAN Committee on Nutrition all
recommend exclusive breastfeeding until 6 month of age.1 If
human milk is not available, in developed countries infant formula
is the safe alternative even if observational studies have revealed
small health disadvantages in formula-fed compared to breast-fed
infants. Even after adjustment for socio-economic factors, breast-
fed infants have better cognitive development,2,3 and a lower
incidence of infections4 compared with formula-fed suggesting
that components of human milk, lacking or present at lower
concentrations in infant formula, are needed for optimal devel-
opment of the brain and the immune system. Some of the likely
components are present in the milk fat globule membrane
(MFGM). Sphingomyelin, gangliosides, sialic acid, cholesterol, and
choline are all present in higher/altered concentrations in human
milk compared to infant formulas, are components of the MFGM,
and have been associated with improved brain function in
humans and in animal models.5–15 Further, several of the close to
200 proteins of the MFGM,16 e.g., lactoferrin,17 mucins and
butyrophilin,18 and components of the lipid fraction19 have
immunological and/or antimicrobial functions. The MFGM fraction
has historically been discarded during formula manufacturing
when milk fat has been replaced by blends of vegetable oils.
Recently different MFGM concentrates from bovine milk have
become available and possible to add to infant formulas.
We recently performed a double-blinded randomized con-
trolled trial exploring the effects of feeding infants an experi-
mental formula (EF) supplemented with a bovine MFGM
concentrate from <2 to 6 months of age. Infants fed the EF
performed better on cognitive testing at 12 months of age20 and
had lower incidence of otitis media during the intervention21
compared to infants fed a standard formula (SF).
The aim of the present study was to investigate the lipidome in
serum/plasma and erythrocyte membranes of infants fed EF
compared to infants fed SF and a breast-fed reference (BFR)
group. Our hypothesis was that MFGM supplementation would
affect the lipidome in serum/plasma and cell membranes, and
thus be a likely contribution to the mechanisms mediating the
positive effects of feeding EF on cognitive development and
defense against infections.
METHODS
Sample collection and formulas
As described previously,20 160 formula-fed infants, 80 boys and 80
girls, were randomized to receive either the EF or SF from
inclusion until 6 months of age. Eighty breast-fed infants, 40 boys
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and 40 girls, were recruited as a reference group. Inclusion criteria
were age <2 months, gestational age 37–42 weeks, birth weight
2500–4500 g, and no chronic illness. Infants were either exclu-
sively formula-fed or exclusively breast-fed at inclusion. BabySemp
(Semper AB, Sundbyberg, Sweden) was used as SF and the EF
was modified from this by lowering the energy density from 66 to
60 kcal/100 mL, the protein concentration from 1.27 to 1.20 g/100
mL and by supplementation with a bovine MFGM fraction
(Lacprodan MFGM-10; Arla Foods ingredients, Viby, Denmark),
contributing 4% (wt/wt) MFGM protein of the total protein
content. In both formulas long-chain polyunsaturated fatty acids
were added to the same concentration (arachidonic acid (20:4n-6,
ARA) 15 mg/100ml and docosahexaenoic acid (22:6n-3, DHA) 9
mg/100ml). Infants in the EF group totally compensated for the
lower energy and protein contents of the EF formula by larger
ingested volumes resulting in identical total energy and protein
intakes for the EF and SF groups and only marginally higher total
fat intake for the EF group.20 The intervention was blinded for the
study staff and parents until all infants had passed the study visit
at 12 months of age. Blood samples were collected at 4, 6, and
12 months of age and were obtained >2 h after the latest meal.
The study was approved by the Regional Ethical Review Board in
Umeå. Complete oral and written information was given to the
parents/caregivers, and written consent was obtained from
parents/caregivers of all infants before inclusion. This study was
registered with number NCT00624689 at clinicaltrials.gov. A study
flow chart is presented in Fig. 1. A CONSORT checklist is available
as supplemental material (Supplemental Table S1).
Sample preparation
Venous blood was collected in EDTA and SST tubes. Serum at 4
and 12 months were obtained by centrifugation at 1300× g for
10min and frozen. At 6 months, plasma and erythrocytes were
separated by centrifugation at 2000× g for 10min at 4 °C. After
removal of plasma, the erythrocyte pellet was washed three times
with cold 0.15 M NaCl-1 mM EDTA, pH 7.4. The erythrocytes were
resuspended in the EDTA-NaCl-solution and 10 µl DL-ɑ-tocopherol
(1.6 mg/ml ethanol) was added. Samples were stored at –80 °C.
The plasma, erythrocyte and serum samples lipid extraction was
according to Folch et al.22
To 20 µl of plasma 110 µl of CHCl3:MeOH (2:1 v/v) including
internal standard solution was added. The samples were shaken
for 2 min, and allowed to stand for 30min at room temperature
before centrifugation (14000 rpm, 3 min, 4 °C). A volume of 50 µl of
the lower phase was collected and mixed with 70 µl of CHCl3:
MeOH (2:1 v/v). Extracts were stored at –80 °C.
To 10 µL of serum 10 µL of 0.9% NaCl, 40 µL of CHCl3:MeOH (2:1,
v/v), and 80 µL of an 3.5 µgmL−1 internal standard solution was
added. The samples were vortexed and allowed to stand on ice for
30min after which they were centrifuged (9400× g, 3 min, 4 °C). A
volume of 60 µL from the lower layer of each sample was transferred
to a glass vial with an insert and 60 µL of CHCl3:MeOH (2:1, v/v) was
added. The samples were randomized before analysis.
To 20 µl of erythrocytes, 30 µl of 0.15 M NaCl and 250 µl of
CHCl3:MeOH (2:1 v/v), including internal standards, were added.
The samples were shaken for 2 min, and allowed to stand for
30min at room temperature before centrifugation (14000 rpm, 3
min, 4 °C). After centrifugation 120 µl of the lower phase was
collected and this ready-to-use extract was stored at –80 °C.
Lipidomic analyses and data processing
Plasma at 6 months of age. The following compounds
were used as internal standards: Phosphatidic acid (PA) (17:0/
17:0), Phosphatidylethanolamine (PE) (17:0/17:0), Phosphatidyl-
glycerol (PG) (17:0/17:0), Monoacylglycerol (MG) (17:0/0:0/0:0),
Diacylglycerol (DG) (17:0/0:0/17:0), Triacylglycerol (TG) (17:0/
17:0/17:0), Phosphatidylcholine (PC) (19:0/19:0), and Lyso-PC
(17:0/0:0), TG(16:0/16:0/16:0)-13C3. QC-samples (Quality control
sample, mix of extract from the samples), dilution series of QC
and LIMA-samples (pooled plasma samples from the lab) were
used as a quality check. The samples were analyzed using ultra-
high performance liquid chromatography-quadrupole time-of-
flight/mass spectrometry (UHPLC-QTOF/MS) system (Agilent
Technologies, Santa Clara, CA). Lipids were separated on a
ACQUITY UPLC® CSH C18 column (2.1 × 50 mm, 1.7 µm) (Waters,
Milford, MA) using a method modified from,23 and detected by
an 6540 Q-TOF mass spectrometer in positive ion mode.
Targeted MS data processing was performed using Agilent
MassHunter ProFinder B.06 software (Agilent Technologies). In-
house libraries with masses and internal retention times were
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number of carbons and double bond. For some lipids, each
specific fatty acid tail was detected and is in those cases
presented. An analytic effect in intensity of detection was
observed and data were therefore normalized using the internal
standards.
Serum at 4 and 12 months of age. The following compounds
were used as internal standards: PA(17:0/17:0), PG(17:0/17:0), PE
(17:0/17:0), TG(19:0/19:0/19:0), PC(14:0)-d13, PC(17:0/17:0), TG
(16:0/16:0/16:0)-13C3, Cer(d18:1/17:0), Sphingomyelin (SM)
(d18:1/17:0), Lyso-PC(17:0/0:0), TG(8:0/8:0/8:0)-13C3, PC(16:0-d31/
18:1), Cholesteryl ester (CE) (17:0), Phosphatidylserine (PS) (17:0/
17:0), and TG(15:0/15:0/15:0). The lipidomics analyses were
performed on a UHPLC-QTOF/MS system (Agilent Technologies)
in positive ion mode using a previously described method.24 Data
processing was performed using MZmine 2.17 including detection
and alignment of peaks, peak integration, normalization, and peak
identification.25 Data imputation of missing values was performed
with half of the rows minimum. Lipids were annotated according
to lipid class, total number of carbon and double bonds. For some
lipids each specific fatty acid tail was detected and is in those
cases presented. As a batch effect was observed, i.e., lipid
concentrations varied among batches, the data were normalized
using internal standards.
Erythrocyte membranes at 6 months of age. Two internal
standards were used, TG(16:0/16:0/16:0)-13C3 (in positive mode)
and Cer(d18:1/16:0-d31) (in positive and negative mode). QC-
samples and dilution series of QC was used as a quality check.
Samples were analyzed by UHPLC-QTOF/MS (Agilent 6550) in
positive and negative ion mode. For analysis details and data
processing (in ProFinder B.08) see above for plasma at 6 months.
There was a concentration effect, i.e., a variation in total lipid
concentration among samples, and the data were normalized
using the total sum of lipids.
Statistics. The multivariate analyses at 6 months of age were
based on identified lipids and at 4 and 12 months on both
identified and unidentified lipids. To detect any outliers, principal
component analysis (PCA) was performed. Strong outliers were
identified by Hotelling’s T2. Orthogonal projections to latent
structures discriminant analysis (OPLS-DA) were performed to
detect any class variation in the lipid profile between the groups.
To validate the model cross-validation, permutation test and CV-
ANOVA were used. Significance level was set to CV-ANOVA p <
0.001.26 Multivariate analyses were performed using SIMCA
(SIMCA-P+ 14.1, Umetrics, Umeå, Sweden). Differences in relative
concentrations of specific lipids were analysed using the two-
sided t-test (SPSS statistics 25) of log transformed relative
concentrations and reported as unadjusted p-values. To highlight
specific lipids of interest, a combination of OPLS-DA loadings,
variable importance in the projection (VIP) and the two-sided t-
test were used. Significant levels were set to VIP > 1 and
unadjusted p < 0.001.
RESULTS
Plasma lipidome at 6 months of age
Of the 220 infants still in the study at 6 months of age, lipidomic
analyses of plasma were performed in 213 infants (73 EF, 70 SF, 70
BFR) (Fig. 1). No outliers were detected. There was a clear
separation between the EF and SF groups in the OPLS-DA (Fig. 2).
The separation was mostly due to SM, PC, Cer, and TG. Most of the
phospholipids (PL) and TG species important for the separation
were higher in relative concentration in the EF group compared to
the SF group. Individual lipids with the highest VIP values were
SM, PC, and Cer species (Table 1).
Serum lipidome at 4 and 12 months of age
Analyses were performed on serum samples from a randomly
selected subgroup (n= 90; 30 SF, 30 EF, and 30 BFR) at 4 and
12 months of age (Fig. 1). At 4 and 12 months of age, one sample
was excluded due to analytical problems. No outliers were
detected. At 4 months, there was a clear separation between
the EF and SF groups in the OPLS-DA. The separation was
transient and not detected at 12 months, 6 months after the
intervention ended (Fig. 3). The group separation at 4 months of
age was mostly due to SM and PC, whereas PE and TG contributed
less. Most of the PLs important for the separation were higher in
the EF group compared to the SF group. Individual lipids with the
















Fig. 2 OPLS-DA plot of plasma lipidomics at 6 months for the SF (green circles) and EF (blue circles) groups. OPLS-DA (1+ 4, R2X (cum) 0.651,
R2Y (cum) 1, Q2 (cum) 0.515) CV-ANOVA < 0.001 (uv-scaled), 182 lipids were included in the model. There was a clear separation between the
formula groups
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Erythrocyte membrane lipidome at 6 months of age
Lipidomic analyses on erythrocyte membranes were performed in
213 infants (70 SF, 73 EF, 70 BFR) at 6 months of age (Fig. 1). No
outliers were detected. There was a clear separation between the
two formula groups in the OPLS-DA (Fig. 4). Lipids important for
the separation were mostly SM, PE, and PC species. Relative
concentrations of most of the PLs important for the separation
were higher in the EF group (Table 1).
DISCUSSION
We found significant differences in the serum/plasma lipidome at
4 and 6 months of age in infants fed the EF compared to infants
fed SF. This separation was also detected in erythrocyte
membranes at 6 months, but did not remain in sera collected at
12 months of age, 6 months after the end of the intervention. SM
and PC species contributed most to the separation in serum/
plasma and erythrocyte membranes at 4 and 6 months of age. At
6 months Cer also contributed to the separation in plasma. Most
PCs important for the separation were higher in the EF group as
opposed to Cer and SM species having a more heterogeneous
pattern. In the erythrocyte membrane, PEs also contributed to the
separation and were higher in the EF group. These separations are
reasonably caused by differences in lipid intake between the two
formula groups. We have previously presented, in the same study
population, that the EF group had moderately higher total serum
cholesterol concentration than the SF group at 6 months of age27
due to higher cholesterol intake during the intervention. The
conspicuous difference in the lipidomic profile between the EF
and SF groups at 6 months of age in the present study is unlikely
caused by the higher total fat intake in the EF group, which was
mainly caused by a higher TG intake, but is rather explained by a
clear difference in fat quality due to the MFGM supplementation
of the EF as the lipids important for the separation between the EF
and SF groups are polar lipids present at high concentrations in
the MFGM.
Type of feeding, i.e., breastfeeding or formula-feeding, and type
of fat consumed affect blood lipid profiles in infants. In a
prospective observational cohort study, breast-fed, compared to
formula-fed infants, had a different lipid profile and three lipid
molecular species, PC (35:2), SM (36:2) and SM (39:1), were
suggested to be used collectively as biomarkers indicating
whether infants were formula- or breast-fed.28 In the present
study these lipids had high VIP values and showed the same
pattern when comparing the SF and BFR groups at 4 months,
supporting the role of these lipids as biomarkers of SF feeding vs
breastfeeding. However, the pattern of these lipids differ between
the EF and SF groups indicating that these biomarkers might not
Table 1. Identified lipids with the highest VIP values in the OPLS-DA
Lipid Lipid class VIP value P-value EF vs SF EF/SFa BFR/SFb
6 months, plasma
(182 metabolites, all identified)
SM(d18:1/21:0) SM 2.79 5.41E-20 1.84 0.61
SM(d18:1/14:0) SM 2.43 6.30E-13 1.50 0.88
PC(40:2) PC 2.33 1.10E-12 1.29 0.84
SM(d18:1/15:0) SM 2.15 1.49E-9 1.35 0.98
HexoseCer(d18:1/24:1) Cer 2.05 2.74E-8 0.75 1.48
SM(d18:1/20:0) SM 2.00 5.39E-8 1.35 0.79
SM(d18:0/14:0) SM 1.92 2.20E-8 1.25 1.09
Cer(d18:1/20:0) Cer 1.89 3.38E-7 1.35 0.91
Cer(d18:1/23:0) Cer 1.84 1.43E-8 1.30 0.81
Cer(d18:1/22:0) Cer 1.60 6.39E-5 1.21 0.91
4 months, serum
(484 metabolites in the model, 187 identified)
SM(d39:1) SM 2.39 2.88E-13 1.70 0.57
PC(42:6) PC 2.29 4.18E-9 2.08 0.85
SM(d18:0/14:0) SM 2.16 9.08E-11 1.49 1.26
SM(d32:1) SM 2.11 2.16E-9 1.40 0.90
SM(d33:1) SM 2.08 5.62E-8 1.32 0.92
PC(36:2) PC 1.96 1.40E-6 1.54 0.94
PC(37:2) PC 1.96 2.56E-7 1.58 1.28
PC(35:2) PC 1.95 4.34E-7 1.55 1.26
SM(d18:2/24:1) SM 1.95 9.36E-7 0.77 1.49
PC(35:1) PC 1.93 5.33E-6 1.48 1.51
6 months, Erythrocyte membrane
(112 metabolites, all identified)
SM(d18:1/14:0) SM 2.21 1.86E-17 1.43 0.87
SM(d18:1/20:0) SM 2.16 2.12E-16 1.27 0.91
SM(d18:1/23:0) SM 2.13 3.85E-24 1.29 0.77
PE(38:2) PE 2.10 1.33E-21 1.28 0.92
PE(32:2) PE 2.09 3.09E-13 1.33 0.88
SM(d18:1/15:0) SM 2.08 1.70E-11 1.33 0.89
SM(d18:1/22:1) SM 2.04 5.51E-15 1.18 0.94
PE(40:1) PE 1.97 8.17E-19 1.27 0.79
PC(28:1) PC 1.95 4.43E-12 1.39 0.86
PC(34:0) PC 1.86 3.52E-11 1.10 1.06
aMean relative concentration in EF group divided by mean relative concentration in SF group
bMean relative concentration in BFR group divided by mean relative concentration in SF group
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be valid when comparing infants fed MFGM supplemented
formula with breast-fed infants.
A previous study showed that feeding preterm infants
sphingomyelin-fortified formula resulted in higher SM concentra-
tions and more favorable neurodevelopment,15 and feeding
piglets a formula supplemented with PL and gangliosides resulted
in improved spatial learning and growth of brain tissue.29 Several
differences in the lipidome between the EF and SF groups in our
study are interesting in relation to our previous finding that the EF
group had improved cognitive development compared to the SF
group at 12 months of age.20 Higher relative concentrations of PCs
and some SMs contributed to the separation between the groups,
both in plasma, serum, and erythrocyte membrane. The concen-
trations of several Cer, a metabolite of SMs and other
sphingolipids30 were affected indicating that the metabolism of
sphingolipids was altered. Cognitive function reflects brain
development from fetal life until the time of measurement. A
positive effect on brain development at any time before 12 months
of age may theoretically explain the positive effect on cognitive
function seen in the EF group at this time point. Thus, the clear
lipidomic differences between the EF and SF groups during the
intervention period could be relevant for the effect on cognitive
function even if the effect on the lipidome was transient and not
present at 12 months of age.
The erythrocyte membrane lipidome, which is less affected by
the recent dietary intake and rather reflects long-term lipid
intake,31 was clearly different between the EF and SF groups.
The separation was mostly due to SM, PC, and PE species. A
dietary effect on the erythrocyte membrane lipidome is likely a
proxy for effects on cell membranes in other tissues. Extrapolat-
ing lipidomic observations to the central nervous system must
however be made with caution, since the transport of lipids and
fatty acids over the blood-brain barrier (BBB) is not fully
understood. Two different transport mechanisms have been
implicated, i.e., passive diffusion or transporter proteins.32
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Fig. 3 OPLS-DA plot of serum lipidomics at 4 (circles) and 12 (triangles) months for the SF (green) and EF (blue) groups. OPLS-DA (2+ 4, R2X
(cum) 0.588, R2Y (cum) 0,667, Q2 (cum) 0,414) CV-ANOVA < 0.001 (uv-scaled), 484 lipids, both identified and unidentified, were included in the












Fig. 4 OPLS-DA plot of erythrocyte membrane lipidomics at 6 months for the SF (green circles) and EF (blue circles) groups. OPLS-DA (1+ 1,
R2X (cum) 0.238, R2Y (cum) 1, Q2 (cum) 0.585) CV-ANOVA < 0.001 (uv-scaled), 112 lipids are included in the model. There was a clear
separation between the formula groups
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metabolism of DHA over the BBB. In a recent report, fatty acid
transport protein 1 (FATP 1), localized in the basal membrane of
brain microvessels, was suggested to contribute to the transport
of DHA, taurine, and biotin into the brain.33 DHA attached to
Lyso-PC seems to be the preferred form of DHA taken up by the
brain34 and might be mediated by the transporter Mfsd2a.35
These studies indicate that not only the concentration of a fatty
acid is of importance, but also in which form, esterified or non-
esterified, and if esterified, to which lipid affect its transport
across the BBB. The association between the lipidome in
blood and central nervous system is not fully understood.
However, in a Finnish study, erythrocytes, retinal cells, and
cells from the optic nerve from nine humans were collected.
Several lipids of the erythrocytes correlated with lipids in ocular
tissue.36
With respect to immunological effects, it is known that PLs play
an important role in modulating gut inflammation,37 and also
affect the inflammatory response in the lungs during pulmonary
infection.38 Sphingolipid metabolites, Cer, and sphingosine-1-
phosphate, regulate immune cell trafficking and epithelial
integrity and therefore are important in inflammation and
inflammatory diseases.30 Changes in SM and its metabolite Cer
affect T-cell response, both in early activation steps and effector
functions.39 Our intervention did affect the lipidome of erythro-
cyte membranes, where alteration of SMs contributed, thus
suggesting that the lipid composition of cell membranes of
immune cells are affected similarly. We also found an effect on SM
and Cer in plasma at 6 months of age. An improved cell function
due to the altered lipid composition of the cell membrane is a
likely part of the mechanism behind the positive effect on the
immune system previously reported in the same study
population.21
A strength of the current study is the double-blinded
randomized design and the longitudinal aspect. Besides the
analyses of plasma and erythrocyte membranes at 6 months of
age, we analyzed the serum lipidome both at 4 months of age,
when the intervention was at its maximum, and at 12 months of
age, 6 months after the intervention. This made it possible to
study both direct and possible long-term effects on the lipidomes.
Another strength was the low drop-out rate.
All analyses were performed on an intention-to-treat basis. As
previously described,20 a majority of the parents introduced taste
portions of solid food between 4 and 6 months of age in accord
with the Swedish National Food Agency recommendations. Some
parents stopped the study formula due to various symptoms, and
breastfeeding was partly or totally stopped for some of the infants
in the BFR group. This dilution of the intervention is a limitation of
the study but gives an estimate of the effect on the population
level.
The blood samples were stored at –80 °C for 3–9 years until
analysis. As previously described, the lipid components are stable
during long-term storage at −80 °C,40 although some effect has
been shown on the concentration of LPC.41 Since the formula-fed
infants were recruited randomly the in between group separation
should not be affected by the storage time.
Since we are using a multivariate analysis method and our
method is limited to identify class of lipid and number of carbons
and bonds, the results regarding specific lipids should be
interpreted with caution. The main purpose of the analysis was
to detect potential differences in the lipidomic profile, not to
identify specific lipids. To confirm and validate specific lipids of
interest, and to match specific lipids between the MFGM fraction
and blood samples, a targeted method should be used.
The intervention of the study is complex including both
supplementation with a bovine MFGM concentrate and adjust-
ments of macronutrients as previously described.20 Any effect of
the intervention may be due to a number of different mechanisms
and it is not possible to separate one part of the intervention from
another. The complex intervention is a limitation for the
interpretation of mechanisms behind the functional outcomes,
which can only be speculative.
In conclusion, we found that feeding infants a formula
supplemented with a bovine MFGM fraction clearly affects their
serum/plasma and erythrocyte membrane lipidomes. Infants fed
the EF had higher concentrations of many PCs and altered
concentrations of SMs. It is reasonable that these changes reflect
or are part of the mechanisms mediating the positive effects on
cognitive development and immune defense previously shown in
the study population. However, to verify this, further studies are
needed to confirm the observed effects of MFGM supplemented
infant formula on infant lipid metabolism and to study the
mechanism behind the functional outcomes in dept.
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